

Takhzyro (lanadelumab-flyo) — HCPCS J0593

CARECOST ESTIMATE · BILLING CHEAT SHEET

Takeda Pharmaceuticals 300 mg / 2 mL prefilled syringe (and 150 mg / 1 mL pediatric) Subcutaneous · HAE prophylaxis **Reviewed:** May 2, 2026

ASP: Q2 2026

HCPCS J0593 1 mg = 1 unit	DOSE 300 units 300 mg SC q2wk · 1 PFS	MODIFIER JZ Single-dose PFS, no waste	ADMIN CPT 96372 SC injection (NOT 96365 IV)	MEDICARE ASP+6% \$86.846 /mg · \$26,053.80/dose
---	---	---	---	---

PROPHYLAXIS ONLY — NOT for acute attacks. Takhzyro prevents HAE attacks; it does not abort them. Every patient still needs an on-demand rescue: Berinert (J0597 IV), Ruconest (J0596 IV), Firazyr/Sajazir (Q4084 SC), or Kalbitor (J1290 SC).

CODES & PRESENTATIONS

HCPCS	J0593 — "Inj., lanadelumab-flyo, 1 mg" (permanent)
ADULT PFS	300 mg / 2 mL single-dose prefilled syringe
PEDIATRIC PFS	150 mg / 1 mL single-dose prefilled syringe (2–<12 yr)
ROUTE	Subcutaneous (SC) — thigh / abdomen / upper arm
BENEFIT	Medical (first dose / clinic) or pharmacy/specialty (self-admin, most common)

DOSING

- Adults & ≥12 yr: **300 mg SC q2wk**
- After ≥6 mo attack-free: extend to **300 mg SC q4wk**
- Pediatric 2–<12 yr: **150 mg SC q4wk**
- Bill 1 mg = 1 unit (300 or 150 units per dose)
- q2wk: 26 doses/yr; q4wk: 13 doses/yr
- No premedication routinely required

HAE CLASS COMPARISON

DRUG	HCPCS	ROUTE · FREQUENCY	ROLE
Takhzyro	J0593	SC q2wk–q4wk	Prophy
Cinryze	J0598	IV q3–4d	Prophy
Haegarda	J0599	SC q3–4d	Prophy
Berinert	J0597	IV per attack	On-demand
Ruconest	J0596	IV per attack	On-demand
Firazyr/Sajazir	Q4084	SC per attack	On-demand
Kalbitor	J1290	SC per attack	On-demand

Takhzyro = mAb prophy. Differentiates from C1-INH replacement therapies (Cinryze, Haegarda) by mechanism (anti-kallikrein) and dosing convenience (q2wk–q4wk vs q3–4d).

ICD-10 — HAE

CODE	FOR
D84.1	Defects in the complement system — primary, most commonly used
D89.49	Other complement disorder (alternate)
T78.3XXA/D/S	Angioneurotic edema (initial / subsequent / sequela) — secondary, attack history

SELF-ADMIN VS CLINIC ADMIN

SCENARIO	BILL
First dose / training in clinic	J0593 × 300 + JZ + 96372 (medical)
Self-admin at home (most common)	Pharmacy benefit (NCPDP); no J-code billed by prescriber

Specialty pharmacy is the dominant pathway. Most plans dispense Takhzyro to patient's home after first-dose training; the practice does not bill J0593 or 96372 for self-admin doses.

PAYER REQUIREMENTS (MAY 2026)

PAYER	PA	KEY GATES
UnitedHealthcare	Yes	Lab-confirmed HAE Type I/II + attack history (≥1/mo or ≥1 ER); allergy/immunology consult
Aetna	Yes	Lab or genetic confirmation; specialist consult typical
BCBS plans	Yes	WAO/EAACI guideline-aligned; plan-specific
Medicare Part B	MAC LCD	FDA-labeled HAE indication + ICD-10 D84.1

Diagnostic confirmation gates approval: low C1-INH antigen (Type I) or normal/high antigen + low functional C1-INH (Type II); genetic test acceptable for ambiguous cases.

ADMINISTRATION & MODIFIERS

CODE	WHEN
96372	Primary for clinic-admin SC injection (non-chemo)
96365 / 96413	NOT appropriate — Takhzyro is SC, not IV
None	Self-admin at home — pharmacy benefit, no admin CPT

JZ on every claim: Single-dose prefilled syringe, no waste at labeled dose. JW does not typically apply.

MEDICARE REIMBURSEMENT (Q2 2026)

FIELD	VALUE
ASP + 6%	\$86.846 / mg (effective 4/1 – 6/30/2026)
300 mg dose	\$26,053.80 (300 × \$86.846)
150 mg pediatric dose	\$13,026.90 (150 × \$86.846)
Annual q2wk (26 doses)	~\$677,400
Annual q4wk (13 doses)	~\$338,700

SITE OF CARE

SETTING	POS	NOTES
Patient home (self-admin)	12	Most common — specialty pharmacy
Allergy/immunology office (first dose)	11	Common; 96372 admin + training
Hospital outpatient	22	Uncommon for SC PFS

PATIENT ASSISTANCE — TAKEDA ONEPATH

- **Takhzyro support line:** 1-833-927-3658
- **Takeda OnePath:** 1-866-861-1750
- **Takhzyro Co-pay Program:** \$0 first dose for eligible commercial; reduced copay thereafter (excludes Medicare/Medicaid/federal)
- **PAP:** Takeda Patient Assistance Foundation (uninsured/underinsured)
- **Foundation funds:** HealthWell HAE fund, US HAEA Patient Support
- **Web:** takhzyro.com / takedaonepath.com

Pending SME review. Staff-authored from primary FDA, CMS, Takeda, and payer sources. Verify each cited source for high-stakes claims until SME (Catherine Rose, CPC) sign-off is complete.